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Abstract
Background: Higher serological prevalence rates of helicobacter pylori (H. pylori) infection have been reported in
patients with type 1 diabetes (T1DM) and autoimmune thyroiditis (AT). Patients with T1DM are at increased risk for
developing other autoimmune diseases, most commonly AT. It is unknown whether H. pylori infection could
explain the high prevalence of thyroid autoantibodies and AT in T1DM. The aim of the current study was to
evaluate anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin (anti-Tg) autoantibodies in correlation with anti-
H. pylori IgG and IgA in young patients with T1DM.
Methods: Anti-H. Pylori IgG, IgA, anti-TPO and anti-Tg antibodies titers were measured in 162 euthyroid patients
with T1DM and 80 healthy controls matched for age, sex and socioeconomic status.
Results: Seroprevalence of H. pylori was significantly higher in patients with T1DM than in healthy controls; 79%
vs. 51.2%, p < 0.001. Anti H. pylori IgG was positive in 61.1% of patients with T1DM and 30% of controls, p < 0.001,
anti H. pylori IgA was positive in 74% of patients with T1DM and 32.5% of controls, p < 0.001. Thyroid
autoimmunity was also significantly higher in patients with T1DM than in controls; 56.7% vs. 6.2%, p < 0.001. Anti-
TPO was positive in 25.3% of patients with T1DM and 3.7% of controls, p < 0.001, anti-Tg was positive in 47.5% of
patients with T1DM and 6.2% of controls, p < 0.001. With simple and multiple regression analysis anti-H. pylori IgG
and IgA titers were positively and significantly correlated with Anti-TPO and anti-Tg titers in patients with T1DM.
Conclusion: our results support the idea of a connection between H. pylori infection and the occurrence of anti-
TPO, anti-Tg autoantibodies and AT in young patients with T1DM. So, H. pylori infection could be considered as an
environmental trigger for development of AT in T1DM. Young patients with T1DM should be screened for H. pylori
infection.
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Background
Helicobacter pylori (H. pylori) is one of the most com-
mon chronic infections worldwide [1,2]. It affects
approximately 50% of the world population and more
prevalent in developing than in developed countries [3],
however, the majority of infected subjects develop no
clinical symptoms [4]. H. pylori specifically colonizes the
gastric epithelium and causes chronic gastritis, peptic
ulcer disease and/or gastric malignancies [5]; moreover,
it has been epidemiologically linked to some extradiges-
tive diseases [6]. Higher serological prevalence rates of
H. pylori infection have been previously reported in
patients with type 1 diabetes (T1DM) [7] and autoim-
mune thyroiditis (AT) [8].
Patients with T1DM are at increased risk for developing
other autoimmune diseases, most commonly AT [9,10]. Up
to 20% of patients with T1DM have positive anti-thyroid
antibodies; anti-thyroglobulin (anti-Tg) and anti-thyroid
peroxidase (anti-TPO) antibodies and 2 to 5% of patients
with T1DM develop autoimmune hypothyroidism [11].
Thus, the question arises is whether H. pylori infec-
tion could be a reason for the increased prevalence of
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considered as an environmental trigger for development
of AT. The aim of the present study was to evaluate
anti-TPO and anti-Tg autoantibodies in correlation with
anti-H. pylori IgG and IgA in young patients with
T1DM.
Methods
Selection of patients with T1DM and healthy controls
One hundred and sixty two euthyroid patients with
T1DM (90 female and 72 male; mean age: 19.35 ± 2.6
years; diabetes duration: 7.29 ± 7.9) attending out-
patient diabetes clinics at Pediatric and Specialized Med-
ical Hospitals, Mansoura University, Egypt were studied
(Table 1). The diagnosis and clinical classification of dia-
betes mellitus were based on the guidelines of the
American Diabetes Association [12]. Eighty healthy par-
ticipants matched for age, sex and socioeconomic status,
coming from the same geographic area, were evaluated
as controls. A validated questionnaire concerning the
presence of dyspeptic symptoms (epigastric pain, bloat-
ing, post prandial fullness, nausea and vomiting) was
administered. All participants signed an informed con-
sent to be included in our study. This study was
approved by the local ethical committee.
Exclusion criteria: None of the patients had goiter,
known peptic ulcer disease or complications attributable
to diabetic vasculopathy. None of the diabetic or control
subjects used antibiotics, anti-inflammatory drugs (which
may interfere with dyspeptic symptoms), prokinetics or
proton pump inhibitors in the 2 months before testing.
Biochemical and antibodies assay
Free-thyroxine (FT4) and thyroid stimulating hormone
(TSH) were measured by electro-chemiluminecent
immunoassay, using Elecsys 2010, Roche Diagnostic,
Germany. Glycated hemoglobin A1c (HbA1c) was mea-
sured as an index of metabolic control on a DCA 2000
analyzer. Fast ion exchange resin supplied by human
(Germany). The normal range was 4.4%- 6.4%.
Serum anti-H. pylori antibodies IgG and IgA were
assayed by sequential ELISA method supplied by Mono-
bind Inc (USA). Results were considered positive when
the titers were higher than 20 u/ml. Anti-TPO and anti-
Tg autoantibodies were estimated by immunoenzymatic
assay supplied by Diametra Italy. Results were consid-
ered positive when the titers were higher than 20 Au/ml
and 4 Au/ml respectively.
Patients with T1DM and healthy control were consid-
ered to be H. pylori positive when anti-H. pylori IgG
and/or IgA were positive and showing signs of thyroid
autoimmunity when anti-TPO and/or anti-Tg were
positive.
Statistical analysis
Data entry and analyses were performed using SPSS sta-
tistical package version 10 (SPSS, Inc., Chicago, IL, USA).
The quantitative data were presented as a mean and stan-
dard deviation and the qualitative data were presented as
number and percentage. The chi-square (c
2)w a su s e dt o
find the association between qualitative data. Student’st -
test was conducted to compare the mean of continuous
variable in two groups. Odds ratio was calculated to
determine risk of occurrence with 95% confidence inter-
val. Simple correlation and multiple regression analysis of
anti-H. pylori IgG and IgA antibodies titers with other
parameters in patients with T1DM were also performed.
P value of < 0.05 indicates significant.
Results
Clinical and biochemical characteristics of the study
subjects
Seroprevalence of H. pylori was significantly higher in
patients with T1DM than in healthy controls [79% (128/
162) vs. 51.2% (41/80), p < 0.001]. Anti- H. pylori IgG
was positive in 61.1% (99/162) of patients with T1DM
and 30% (24/80) of controls, p < 0.001, anti-H. pylori
IgA was positive in 74% (120/162) of patients with
T1DM and 32.5% (26/80) of controls, p < 0.001 [Figure
1]. There was no statistic significant difference in the
prevalence of dyspeptic symptoms between patients with
T1DM and healthy controls (4.3% vs. 3.7%, p = 0.83).
The mean ± SD of HbA1c levels during the study per-
iod were 8.2 ± 1.75 [Table 1].
Thyroid autoimmunity was significantly higher in
patients with T1DM than in healthy controls [56.7%
Table 1 Clinical and Biochemical Parameters of the study subjects





Age (years) 19.35 ± 2.6 19.76 ± 2.76 0.3
Females (%) 55.5% (90/162) 55% (44/80) 0.93
Gastrointestinal symptoms 4.3% (7/162) 3.7% (3/80) 0.83
Duration of diabetes (years) 7.29 ± 7.9 _
HbA1c (%) 8.2 ± 1.75 _
Data are expressed as mean ± standard deviation, numbers or percentages, T1DM; type 1 diabetes mellitus, HbA1c; glycated hemoglobin.
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tive in 25.3% (41/162) of patients with T1DM and 3.7%
(3/80) of controls, p < 0.001, anti-Tg was positive in
47.5% (77/162) of patients and 6.2% (5/80) of controls, p
< 0.001 [Figure 1].
Comparison between H. pylori positive and H. pylori
negative patients with T1DM
Patients with T1DM were divided, according to H.
pylori status, into 2 groups: H. pylori positive and H.
pylori negative. The 2 groups were compared for age,
duration of diabetes, thyroid autoimmunity, anti-TPO
and anti-Tg autoantibodies. There was no significant
difference in age between H. pylori positive and nega-
tive patients with T1DM. The mean T1DM duration
and HbA1c were significantly greater in H. pylori posi-
tive than in H. pylori negative patients with T1DM
(8.9 ± 8.6 vs. 4.22 ± 2.35, p < 0.001; 8.3 ± 1.58 vs. 6.8
±2 . 3 ,p<0 . 0 0 1r e s p e c t i v e ly). Thyroid autoimmunity
( 6 3 . 2 %v s .3 2 . 3 % ,O R3 . 6 ,9 5 %C I :1 . 5 -8 . 7 ,p=0 . 0 0 2 ) ,
anti-TPO (28.9% vs. 11.7%, OR 3.05, 95% CI: 0.93-11.1,
p = 0.04) and anti-Tg (53.1% vs. 26.4%, OR 4.7, 95%
CI: 1.87-12.2, p < 0.001) were significantly higher in H.
pylori positive compared to H. pylori negative patients
with T1DM [Table 2]. With respect to sex, anti-TPO
and anti-Tg antibodies (38.3% vs. 12.7%, OR 4.27, 95%
CI: 1.57-11.9, p = 0.002; 68.4.9% vs 32.7%, OR 4.47,
95% CI: 1.9-10.17, p < 0.001 respectively) were higher
in female H. pylori positive patients with TIDM than
in males.
Comparison between thyroid autoimmunity positive and
thyroid autoimmunity negative patients with T1DM
Patients with T1DM were divided, according to thyroid
autoimmunity status, into 2 groups: thyroid autoimmu-
nity positive and thyroid autoimmunity negative. The 2
groups were compared for age, duration of diabetes, H.
pylori seopositivity, anti-H. pylori IgG and IgA antibo-
d i e s .W i t hr e g a r dt oa g e ,d u r a t i o no fd i a b e t e sa n d
HbA1c, there were no statistic significant differences
between thyroid autoimmunity positive and thyroid
autoimmunity negative groups. In patients with positive
thyroid autoimmunity as compared to autoimmunity
negative, significantly higher H. pylori seopositivity
(92.3% vs. 61.4%, OR 7.6, 95% CI: 2.8-12.6, p < 0.001),
anti-H. pylori IgG (70.6% vs. 48.5%, OR 2.5, 95% CI:
1.27-5.15 p = 0.007) and IgA (86.9% vs. 57.1%, OR 5,
95% CI: 2.18-11.6, p < 0.001) were found [Table 3].
With respect to sex, only IgG (82.5% vs. 44.8%, OR 5.8,
95% CI: 1.97-17.5, p < 0.001) was higher in female
patients with thyroid autoimmunity than in males.
Simple correlation and multiple regression analysis of
anti-H. pylori IgG and IgA antibodies titers with other
parameters in patients with T1DM
Anti-H pylori IgG and IgA titers were insignificantly
correlated with diabetes duration (r = 0.05, p = 0.85; r =
0.07, p = 0.79 respectively) and HbA1c (r = 0.21, p =
0.35; r = 0.19, p = 0.41 respectively). Anti-H. pylori IgG
and IgA titers were positively correlated with anti-TPO
(r = 0.75, p < 0.001; r = 0.53, p < 0.004 respectively)
[Figure 2] and anti-Tg autoantibodies titers (r = 0.39, p
= 0.02; r = 0.36, p = 0.041 respectively) [Figure 3].
With multiple regression analysis anti-TPO and anti-
Tg autoantibodies titers remained independently corre-
lated with anti-H. pylori IgG and IgA titers [Table 4].
Discussion
T h ec u r r e n ts t u d ys h o w sah i g h e rs e r o p r e v a l e n c eo fH .
pylori infection in Egyptian patients with T1DM when
compared with control participants, matched for age,
sex and socioeconomic status. H. pylori infection was
asymptomatic and was significantly associated with dia-
betes duration and poor glycemic control.
Our results are consistent with previous reports of
high prevalence of H. pylori infection in young patients
with T1DM [7,13-15] and are in contrast with others
which did not demonstrate any difference between the
prevalence of H. pylori in patients with diabetes and
healthy controls [16,17].
We found no significant difference in the dyspeptic
symptoms between patients and healthy controls. The
relationship between gastrointestinal symptoms in dia-
betes and H. pylori infection is controversial. According
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Figure 1 Seoprevalence of anti-H. pylori and anti-thyroid
antibodies in patients with type 1 diabetes and healthy
controls, * P is significant if < 0.05.
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Page 3 of 7and non-diabetics concerning the prevalence of H.
pylori-related gastroduodenal disorders [18]. On the
other hand, some data demonstrated a higher prevalence
of H. pylori infection in diabetic patients with dyspepsia
as compared with non-diabetics [19].
In agreement with other reports [7,19] this study
shows that H. pylori seropositivity was significantly asso-
ciated with the duration of diabetes. Moreover, HbA1c
levels were significantly greater in H. pylori positive
patients with T1DM than in H. pylori negative. This is
in line with Toporowska-Kowalska et al. [14] and dis-
agrees with Candelli et al. [20]. The poor glycemic con-
trol in H. pylori infected patients could be attributed to
the increased production of pro-inflammatory cytokines
[21] induced by H. pylori gastric infection itself. On the
other hand, alteration in glucose metabolism may pro-
mote H. pylori colonization [22].
The high prevalence of H. pylori infection in patients
with diabetes is generally explained by reduced gastric
motility and peristaltic activity which may promote H.
pylori colonization [22], various chemical changes in
gastric mucosa following non-enzymatic glycosylation of
mucins or increased sialic acid [23] which may be
involved as a receptor for H. pylori on the cell surface
by promoting adhesion of H. pylori to gastric mucosa
cells [24] and an impaired non-specific immunity
observed in patients with diabetes [25].
In the present study, thyroid autoimmunity was signif-
icantly higher in patients with T1DM than in healthy
controls; the prevalence rates of anti-TPO and anti-Tg
antibodies in T1DM patients of our study were 25.3%
and 47.5% respectively.
These results are in accordance with previous reports
[9,10,26]. Very recently, Ghawil et al. [27] documented
that 23.4% of Libyan TIDM patients had positive anti-
TPO antibodies and 7% had positive anti-Tg antibodies.
In Iran, Sharifi et al. [28] found that 39.6% of TIDM
patients had positive anti-TPO antibodies and 30% had
positive anti-Tg antibodies.
Of interest we noted an association between H. pylori
and anti-thyroid antibodies; anti-TPO and anti-Tg auto-
antibodies were significantly elevated in the group of H.
pylori seropositive patients with T1DM. On the other
hand, patients with T1DM with laboratory signs of thyr-
oid autoimmunity had elevated anti-H. pylori IgG and
IgA. In addition, anti-H. pylori IgG and IgA titers were
significantly and independently correlated with anti-
TPO and anti-Tg titers; the strong positive relations
between these antibodies titers suggest that H. pylori
infection might be involved in the development of AT
in young patients with T1DM.
Our results are consistent with most previous studies
[8,29-31] reporting a connection between H. pylori
infection and autoimmune thyroiditis. Larizza et al. [32]
found a significant interaction between HLA-
DRB1*0301, a well-known marker of autoimmunity, and
H. pylori infection in patients with AT and not controls.
This allele has been specifically involved in both cellular





OR 95% CI P- value
Age (years) 20.1 ± 4.6 19.8 ± 4.34 - - 0.72
Duration of diabetes (years) 8.9 ± 8.6 4.22 ± 2.35 - - < 0.001*
HbA1c (%) 8.3 ± 1.58 6.8 ± 2.3 < 0.001*
Thyroid autoimmunity (+) 63.2% (81/128) 32.3% (11/34) 3.6 1.5:8.7 0.002*
Anti-TPO (+) 28.9% (37/128) 11.7% (4/34) 3.05 0.93: 11.1 0.04*
Anti-Tg (+) 53.1% (68/128) 26.4% (9/34) 4.7 1.87: 12.2 < 0.001*
Data are expressed as mean ± standard deviation, numbers or percentages. H.P; helicobacter pylori, OR; odds ratio, CI; confidence interval, HbA1c; glycated
hemoglobin, Anti-TPO; anti-thyroid peroxidase, Anti-Tg; anti-thyroglobulin, * P is significant if < 0.05.
Table 3 Clinical and biochemical parameters in thyroid autoimmunity positive and thyroid autoimmunity negative
patients with T1DM
Parameters Thyroid autoimmunity positive (n = 92) Thyroid autoimmunity negative(n = 70) OR 95% CI P- value
Age (years) 19.37 ± 2.8 19.32 ± 2.45 - - 0.92
Duration of diabetes (years) 7.37 ± 2.87 7.12 ± 2.79 - - 0.54
HbA1c (%) 8.2 ± 1.7 7.85 ± 1.95 0.15
H. pylori positive(+) 92.3% (85/92) 61.4% (43/70) 7.6 2.8: 12.6 < 0.001*
Anti- HP IgG (+) 70.6% (65/92) 48.5% (34/70) 2.55 1.27:5.15 0.007*
Anti- HP IgA (+) 86.9% (80/92) 57.1% (40/70) 5 2.18:11.6 0.001*
Data are expressed as mean ± standard deviation, numbers or percentages. OR; odds ratio, CI; confidence interval, HbA1c; glycated hemoglobin, Anti- H.P IgG;
anti-helicobacter pylori IgG, Anti- H.P IgA; anti-helicobacter pylori IgA, * P is significant if < 0.05.
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Page 4 of 7and humoral reactions against self structures such as
thyrocytes [33]. Furthermore, our results are parallel
those of Triantafillidis et al. [34], who found a relation-
ship between H. pylori infection and the presence of
high titers of anti-TPO and anti-Tg autoantibodies.
Decrease of antithyroid autoantibodies titers has been
observed in patients with AT after eradication of H
pylori infection [29].
On the contrary, other studies showed no differences
in the serum levels of thyroid autoantibodies in patients




Anti- HP Ig A titer
Anti-TPO titer 






Figure 2 correlations of anti-H. pylori IgG and IgA titers with anti-TPO titer, * P is significant if < 0.05.
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Figure 3 correlations of anti-HP IgG and IgA titers with anti-Tg titer, * P is significant if < 0.05.
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Page 5 of 7with and without H. pylori infection [35,36]. Moreover,
Franceschi et al. [35] found a similar prevalence of H.
pylori infection in patients with Hashimoto’s thyroiditis
and controls.
In our patients’ group we found no significant associa-
tion between thyroid autoimmunity and age or the dura-
tion of diabetes. The highest prevalence of thyroid
antibodies in patients with T1DM was observed after
the age of 15 years [37-39]. It is known that the maxi-
mum autoimmune activity is observed during puberty
[40]. In agreement with our results, Kordonouri et al.
[38] found insignificant role of diabetes duration in the
development of thyroid autoimmunity.
We have noticed a significant association between the
thyroid autoimmunity with female sex in H. pylori posi-
tive patients with T1DM. This is Consistent with De
Block et al. [37] who reported a 3-fold risk of anti-TPO
antibody positivity in female adolescents and young
adults with diabetes in comparison with males. Similar
findings were reported by Kordonouri et al. [26,38]. In
patients with T1DM [41] oestradiol seemed to accelerate
the progression of autoimmune diseases via enhancing
the pathway of T helper type 2 cells, while androgens
had a protective effect [40].
The etiologic causes for autoimmune thyroiditis
development are multifactorial, involving genetic pre-
disposition [33,42] and external factors, most common
being infections such as H. pylori [8]. The putative
mechanism to explain how H. pylori infection in the
stomach can pathogenically influence remote organs is
the induction of an autoimmune reaction by cross
reactivity with thyroid antigens [43]. Moreover, H.
pylori infection induces an acute polymorphonuclear
infiltration in the gastric mucosa. If the infection is not
effectively cleared, this acute cellular infiltrate is gradu-
ally replaced by an immunologically-mediated, chronic,
predominantly mononuclear cellular infiltrate [44]. The
latter is characterized by the local production and sys-
temic diffusion of pro-inflammatory cytokines [21],
which may exert their effect in remote tissues and
organs [45]. Therefore, a pathogenic link between H.
pylori infection and diseases characterized by activa-
tion of inflammatory mediators and or induction of
autoimmunity might exist [46].
Conclusion
results of this study support the idea of a connection
between H pylori infection and the occurrence of anti-
TPO, anti-Tg autoantibodies and AT in young patients
with T1DM, so helicobacter pylori infection could be
considered as an environmental trigger for development
of AT in T1DM. Young patients with T1DM should be
screened for H. pylori infection.
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